Orchard Therapeutics plc

No trades
See on Supercharts
Market capitalization
186.09MUSD
−6.19USD
−150.567MUSD
22.641MUSD
Beta
0.26

About Orchard Therapeutics plc

CEO
Bobby Gaspar
Headquarters
London
Employees (FY)
166
Founded
2018
ISIN
US68570P2002

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Performance
Revenue to profit conversion
No revenue here
This company hasn't generated any revenue in the last financial year
Debt level and coverage
Earnings
Next:
‪0‬
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
OANDA
Forex
4.6Excellent
Learn more
FOREX.com
4.4Very Good
Learn more
Interactive Brokers
Stocks, Futures, Bonds
4.3Good

See all brokers